Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NST changes name; takes $13.3m

This article was originally published in Clinica

Executive Summary

Molecular imaging and drug development company NST NeuroSurvival Technologies has completed a $13.3m financing round, bringing the total investment received to $40m. The funds, provided by a group of existing shareholders, will be used to support phase III clinical trials of the company's ML-10 compound used for molecular imaging of apoptosis (programmed cell death). In conjunction with the financing, the Petach-Tikva, Israel-based firm has changed its name to Aposense to better reflect its focus on apoptosis-targeting technology.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel